Latest news with #BPCI
Business Wire
2 days ago
- Business
- Business Wire
Cave Consulting Group's (CCGroup) Midwest Health System Client Has Superior Performance Results for Knee/Hip Replacement Surgery
SAN MATEO, Calif.--(BUSINESS WIRE)--'Using our extensive benchmarking database, CCGroup identifies a Midwest health system client as being in the upper performance tier for treating lower extremity joint replacements (LEJR) under the CMS Transforming Episode Accountability Model (TEAM),' stated Dr. Douglas G. Cave, President/CEO of CCGroup. 'The CCGroup-CMS Region LEJR bundle average is $20,500, while our client's average is $17,000 (or 17% more efficient),' stated Yuri Alexandrian, COO of CCGroup. He continued, 'Our health system client participated in the CMS Bundled Payments for Care Improvement (BPCI) initiative for knee/hip replacement. During this time, the health system implemented a new operating model where knee/hip replacement surgery moved from inpatient facility to outpatient facility and ambulatory surgery center (ASC) settings. Now, our client is mandated to participate in CMS TEAM bundles payment.' CCGroup determines LEJR TEAM bundle results using the CCGroup-CMS Innovator Project. 'The CCGroup-CMS Innovator Project is a Cloud/SaaS Subscription Model offering that has efficiency and quality results for most practicing specialists in the United States,' explained Dr. Cave. 'The CCGroup-CMS Region LEJR bundle average is $20,500, while our client's average is $17,000 (or 17% more efficient),' stated Yuri Alexandrian, COO of CCGroup. A main reason for bundle efficiency improvement is the significant movement from inpatient to outpatient facility for our client's LEJR bundles. For instance, the CCGroup-CMS Region average is 55 admissions per 100 LEJR bundles as compared to our client's average of 23 admissions per 100 LEJR bundles. 'This finding decreases our client's average inpatient cost to $3,300 per bundle as compared to the peer group's average of $8,300 per bundle (or 60% less),' explained Mr. Alexandrian. Dr. Cave mentioned, 'Inpatient facility reduction is only half the battle to achieving a high performance bundle rating. A health system also needs to reduce adverse events as measured by unplanned hospital readmissions and the CMS patient safety and adverse events (PSAE) composite. Our client's PSAE composite is 30% of all LEJR bundles, while the CCGroup-CMS Region PSAE composite is 19% (both are higher than expected). The key adverse event category is complications directly related to surgery. Our client understands the need to address ASC quality improvement.' Moreover, during the 30-day follow-up period, health systems must address the appropriate post-acute care level of rehabilitation facility and home health care (Rehab/HHC) services. Mr. Alexandrian defined, 'In many instances, we observe savings achieved from lower LEJR inpatient facility utilization that is mostly offset by overutilization of Rehab/HHC services. However, this is not the case for our client where the average Rehab/HHC amount is $775 per bundle as compared to the peer group of $1,200 per bundle (or 35% less).' CCGroup benchmark results show average Rehab/HHC per LEJR bundle varies from $450 to $3,100 – over a 6-fold difference. Future press releases will address CCGroup client-related results for CMS TEAM surgical hip femur fracture treatment, spinal fusion, coronary artery bypass graft, and major bowel procedure. About Cave Consulting Group, Inc. (CCGroup) Cave Consulting Group, Inc. is a software and consulting firm located in San Mateo, California. The company is focused on improving the efficiency (cost-of-care) and effectiveness (quality-of-care) of the healthcare delivery system. Senior management of CCGroup has assessed the performance of physicians and hospitals for over 33 years for health systems, provider groups, CINs, ACOs, health plans, HMOs, and TPAs.
Irish Examiner
07-05-2025
- Business
- Irish Examiner
Ireland ready to be global leader in high-value biopharma services
A new BioPharma Business Services (BBS) strategy will be launched today for Ireland's biopharmaceutical and chemical sector. The strategy aims to position Ireland as a hub for global services by leveraging the country's position as a leading manufacturing location and diversifying and strengthening the industry ecosystem in the country. BioPharmaChem Ireland (BPCI), the Ibec group that represents the sector, launches the strategy at the Impact 2025 conference and awards taking place at the Killashee House Hotel in Naas. Nearly 9,500 professionals, representing close to 20% of total BioPharmaChem employment in Ireland, work in BBS. BBS is one of the fastest growing industry segments, expected to grow by 10% by 2027. "Our new strategy focuses on value stream enhancement, talent development, cutting-edge digital and AI infrastructure, and a vibrant ecosystem, to position Ireland as the global leader in innovative, high-value biopharma services," said Pfizer finance and global business services vice president Aoife Allen, who is the chair of BPCI's BBS steering committee. More than 300 life science professionals are attending the conference in Naas. "It's an important time for the ecosystem to come together to understand the challenges and explore opportunities to support the development of the industry," said BioPharmaChem Ireland director Sinead Keogh. "To ensure competitiveness, it is vital that Ireland prioritises investments in critical areas such as skills and talent, energy and infrastructure, public sector research and innovation, and regulatory simplicity. We welcome the new Government's commitment to a National Life Sciences Strategy and Action Plan on Competitiveness and Productivity. These priorities must remain at the forefront of policy agendas to secure the sector's long-term resilience."
